Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Titan Biotech's Enterprise Value is ₹16,605 Mil.
Titan Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹391 Mil. Therefore, Titan Biotech's EV-to-EBIT ratio for today is 42.48.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Titan Biotech's Enterprise Value is ₹16,605 Mil.
Titan Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹440 Mil. Therefore, Titan Biotech's EV-to-EBITDA ratio for today is 37.73.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Titan Biotech's Enterprise Value is ₹16,605 Mil.
Titan Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,062 Mil. Therefore, Titan Biotech's EV-to-Revenue ratio for today is 8.05.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Titan Biotech's Enterprise Value is ₹16,605 Mil.
Titan Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Titan Biotech's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Titan Biotech (BOM:524717) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Titan Biotech's current Enterprise Value is ₹16,605 Mil.
Titan Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹391 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Titan Biotech's current Enterprise Value is ₹16,605 Mil.
Titan Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹440 Mil.
Titan Biotech's current Enterprise Value is ₹16,605 Mil.
Titan Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,062 Mil.
Titan Biotech's current Enterprise Value is ₹16,605 Mil.
Titan Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Titan Biotech's current Enterprise Value is ₹16,605 Mil.
Titan Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech Enterprise Value Related Terms
Titan Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Titan Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Titan Biotech's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Enterprise Value of ₹16,605 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Titan Biotech and its competitors.
Is Titan Biotech's Enterprise Value too high?
Titan Biotech's current Enterprise Value is ₹16,605 Mil. Overall, Titan Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Enterprise Value compare to VRTX and REGN?
Titan Biotech's Enterprise Value of ₹16,605 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Titan Biotech and its competitors. Titan Biotech's current Enterprise Value is ₹16,605 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.74, compared to a current price of ₹400.95 — trading 177% above its estimated fair value. The current Enterprise Value is ₹16,605 Mil. Titan Biotech's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Enterprise Value is ₹16,605 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹400.95 is trading 177% above its estimated GF Value™ of ₹144.74.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Enterprise Value: ₹16,605 Mil
GF Value™: ₹144.74 vs. price of ₹400.95 (177% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
58GF Score
Get the complete analysis for BOM:524717
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
